B. Metzler seel. Sohn & Co. AG Invests $3.19 Million in DexCom, Inc. $DXCM

Key Points

• B. Metzler seel. Sohn & Co. AG acquired 47,413 DexCom shares during the second quarter, valued at approximately $3.19 million. Institutional investors and hedge funds collectively own 97.75% of the company.
• Analysts maintain a broadly bullish outlook, with DexCom receiving a consensus “Moderate Buy” rating and an average price target of $88.71.
• DexCom exceeded quarterly expectations, reporting $0.70 in EPS and $1.31 billion in revenue, while revenue increased 13.1% year over year.

B. Metzler seel. Sohn & Co. AG acquired a new stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 47,413 shares of the medical device company's stock, valued at approximately $3,193,000.

Other institutional investors also recently bought and sold shares of the company. Reflection Asset Management acquired a new stake in DexCom in the 4th quarter worth about $25,000. Ascentis Independent Advisors purchased a new position in shares of DexCom during the 1st quarter worth about $25,000. MCF Advisors LLC acquired a new stake in shares of DexCom in the fourth quarter worth approximately $32,000. Wellington Grp LLC grew its holdings in DexCom by 778.7% in the first quarter. Wellington Grp LLC now owns 536 shares of the medical device company's stock valued at $34,000 after purchasing an additional 475 shares during the period. Finally, DV Equities LLC acquired a new position in DexCom during the fourth quarter worth approximately $36,000. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently commented on DXCM shares. Bank of America dropped their price objective on DexCom from $100.00 to $80.00 and set a "buy" rating for the company in a report on Monday, May 18th. TD Cowen restated a "buy" rating on shares of DexCom in a research note on Friday, July 31st. Wall Street Zen downgraded DexCom from a "strong-buy" rating to a "buy" rating in a report on Sunday, May 10th. Citigroup reiterated a "buy" rating and set a $88.00 target price (up from $84.00) on shares of DexCom in a report on Friday, July 31st. Finally, Wells Fargo & Company raised their price target on shares of DexCom from $85.00 to $90.00 and gave the company an "overweight" rating in a report on Friday, July 31st. Two analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, DexCom currently has an average rating of "Moderate Buy" and a consensus price target of $88.71.

DexCom Stock Performance

Shares of DXCM stock opened at $92.34 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43. The company's fifty day moving average price is $77.49 and its two-hundred day moving average price is $70.94. The firm has a market capitalization of $34.85 billion, a P/E ratio of 36.50, a P/E/G ratio of 1.56 and a beta of 1.41. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $92.56.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.61 by $0.09. The business had revenue of $1.31 billion for the quarter, compared to analyst estimates of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The company's revenue for the quarter was up 13.1% compared to the same quarter last year. During the same period in the previous year, the company earned $0.48 earnings per share. On average, research analysts anticipate that DexCom, Inc. will post 2.64 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other DexCom news, insider Kevin R. Sayer sold 26,756 shares of the company's stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $76.32, for a total value of $2,042,017.92. Following the transaction, the insider directly owned 328,970 shares of the company's stock, valued at $25,106,990.40. This represents a 7.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 2,000 shares of the stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $85.32, for a total value of $170,640.00. Following the transaction, the director owned 48,852 shares of the company's stock, valued at approximately $4,168,052.64. This trade represents a 3.93% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 73,035 shares of company stock valued at $5,446,673 over the last 90 days. 0.28% of the stock is owned by company insiders.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source